{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:36:09Z","timestamp":1766054169487,"version":"3.48.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Horphag Research Ltd."},{"name":"Open Access funding enabled and organized by Projekt DEAL"},{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40262-025-01582-5","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T16:51:33Z","timestamp":1758991893000},"page":"1827-1842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Physiologically Based Pharmacokinetic Model for the Prediction of Plasma and Bone Tissue Exposure after Prophylactic Administration of Ampicillin\/Sulbactam in Patients with Osteonecrosis of the Jaw"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6551-6569","authenticated-orcid":false,"given":"Maximilian","family":"Stapf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9452-9380","authenticated-orcid":false,"given":"Anton","family":"Straub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1406-9714","authenticated-orcid":false,"given":"Valentin","family":"Steinacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-9231","authenticated-orcid":false,"given":"Oliver","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"issue":"3","key":"1582_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2146\/ajhp120568","volume":"70","author":"DW Bratzler","year":"2013","unstructured":"Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195\u2013283. https:\/\/doi.org\/10.2146\/ajhp120568.","journal-title":"Am J Health Syst Pharm"},{"key":"1582_CR2","unstructured":"Schiegnitz E A-NB, Hoefert S, Otto S, Pautke C, Ristow O, Voss P, Gr\u00f6tz KA: S3 Leitlinie Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ). AWMF-Register-Nr. 007-091. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/007-091l_S3_Antiresorptiva-assoziierte-Kiefernekrosen-AR-ONJ_2018-12.pdf. Accessed 24 Sept 2024."},{"issue":"4","key":"1582_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jormas.2020.05.026","volume":"121","author":"French Society of Stomatology M-FS, Oral Surgery","year":"2020","unstructured":"French Society of Stomatology M-FS, Oral Surgery. French good practice guidelines regarding third molar removal: Indications, techniques, methods. J Stomatol Oral Maxillofac Surg. 2020;121(4):418\u201329. https:\/\/doi.org\/10.1016\/j.jormas.2020.05.026.","journal-title":"J Stomatol Oral Maxillofac Surg."},{"key":"1582_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.895537","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, Liu Y, Yang X, Li C, Song Z. The oral microbiota: community composition, influencing factors, pathogenesis, and interventions. Front Microbiol. 2022;13:895537. https:\/\/doi.org\/10.3389\/fmicb.2022.895537.","journal-title":"Front Microbiol"},{"issue":"1","key":"1582_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1442-2050.2012.01328.x","volume":"26","author":"E Norder Grusell","year":"2013","unstructured":"Norder Grusell E, Dahlen G, Ruth M, Ny L, Quiding-Jarbrink M, Bergquist H, et al. Bacterial flora of the human oral cavity, and the upper and lower esophagus. Dis Esophagus. 2013;26(1):84\u201390. https:\/\/doi.org\/10.1111\/j.1442-2050.2012.01328.x.","journal-title":"Dis Esophagus"},{"key":"1582_CR6","unstructured":"Pfizer Pharma GmbH. Unacid: Prescribing Information. 2024. https:\/\/figi.pfizer.de\/sites\/default\/files\/FI-23383.pdf. Accessed 24 Sept 2024."},{"issue":"1","key":"1582_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.joms.2021.08.147","volume":"80","author":"DM Roistacher","year":"2022","unstructured":"Roistacher DM, Heller JA, Ferraro NF, August M. Is penicillin allergy a risk factor for surgical site infection after oral and maxillofacial surgery? J Oral Maxillofac Surg. 2022;80(1):93\u2013100. https:\/\/doi.org\/10.1016\/j.joms.2021.08.147.","journal-title":"J Oral Maxillofac Surg"},{"issue":"7","key":"1582_CR8","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.jcms.2017.04.001","volume":"45","author":"AK Bartella","year":"2017","unstructured":"Bartella AK, Kamal M, Teichmann J, Kloss-Brandstatter A, Steiner T, Holzle F, et al. Prospective comparison of perioperative antibiotic management protocols in oncological head and neck surgery. J Craniomaxillofac Surg. 2017;45(7):1078\u201382. https:\/\/doi.org\/10.1016\/j.jcms.2017.04.001.","journal-title":"J Craniomaxillofac Surg"},{"issue":"5","key":"1582_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ijantimicag.2013.07.012","volume":"42","author":"S Adnan","year":"2013","unstructured":"Adnan S, Paterson DL, Lipman J, Roberts JA. Ampicillin\/sulbactam: its potential use in treating infections in critically ill patients. Int J Antimicrob Agents. 2013;42(5):384\u20139. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.07.012.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"1582_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01248-22","volume":"67","author":"JA Reeder","year":"2023","unstructured":"Reeder JA, O\u2019Sullivan CT, Xu M, Wu N, Ince D, Rogers WK, et al. Model-informed clinical practice\u2014determining an appropriate ampicillin-sulbactam redosing regimen in surgical patients by utilizing population pharmacokinetics and target attainment analysis. Antimicrob Agents Chemother. 2023;67(4):e0124822. https:\/\/doi.org\/10.1128\/aac.01248-22.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1582_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1751143714564816","volume":"16","author":"S Shah","year":"2015","unstructured":"Shah S, Barton G, Fischer A. Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient. J Intensive Care Soc. 2015;16(2):147\u201353. https:\/\/doi.org\/10.1177\/1751143714564816.","journal-title":"J Intensive Care Soc"},{"issue":"4","key":"1582_CR12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cpt.2202","volume":"109","author":"SG Wicha","year":"2021","unstructured":"Wicha SG, Martson AG, Nielsen EI, Koch BCP, Friberg LE, Alffenaar JW, et al. International Society of Anti-Infective Pharmacology tPKPDsgotESoCMID: from therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109(4):928\u201341. https:\/\/doi.org\/10.1002\/cpt.2202.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1582_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498\u2013509. https:\/\/doi.org\/10.1016\/S1473-3099(14)70036-2.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"1582_CR14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/bcp.15589","volume":"89","author":"S Li","year":"2023","unstructured":"Li S, Xie F. Foetal and neonatal exposure prediction and dosing evaluation for ampicillin using a physiologically-based pharmacokinetic modelling approach. Br J Clin Pharmacol. 2023;89(4):1402\u201312. https:\/\/doi.org\/10.1111\/bcp.15589.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1582_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cpt.37","volume":"97","author":"HM Jones","year":"2015","unstructured":"Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247\u201362. https:\/\/doi.org\/10.1002\/cpt.37.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1582_CR16","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40262-019-00790-0","volume":"58","author":"SA Peters","year":"2019","unstructured":"Peters SA, Dolgos H. Requirements to establishing confidence in physiologically based pharmacokinetic (PBPK) models and overcoming some of the challenges to meeting them. Clin Pharmacokinet. 2019;58(11):1355\u201371. https:\/\/doi.org\/10.1007\/s40262-019-00790-0.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1582_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, et al. Applied concepts in PBPK modeling: how to build a PBPK\/PD model. CPT Pharmacomet Syst Pharmacol. 2016;5(10):516\u201331. https:\/\/doi.org\/10.1002\/psp4.12134.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"8","key":"1582_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.41","volume":"2","author":"H Jones","year":"2013","unstructured":"Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacomet Syst Pharmacol. 2013;2(8):e63. https:\/\/doi.org\/10.1038\/psp.2013.41.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"4","key":"1582_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/jac\/24.4.573","volume":"24","author":"JP Rho","year":"1989","unstructured":"Rho JP, Jones A, Woo M, Castle S, Smith K, Bawdon RE, et al. Single-dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young adult subjects. J Antimicrob Chemother. 1989;24(4):573\u201380. https:\/\/doi.org\/10.1093\/jac\/24.4.573.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1582_CR20","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1128\/AAC.35.10.2098","volume":"35","author":"BR Meyers","year":"1991","unstructured":"Meyers BR, Wilkinson P, Mendelson MH, Walsh S, Bournazos C, Hirschman SZ. Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers. Antimicrob Agents Chemother. 1991;35(10):2098\u2013101. https:\/\/doi.org\/10.1128\/AAC.35.10.2098.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1582_CR21","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1128\/AAC.33.9.1470","volume":"33","author":"RA Blum","year":"1989","unstructured":"Blum RA, Kohli RK, Harrison NJ, Schentag JJ. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother. 1989;33(9):1470\u20136. https:\/\/doi.org\/10.1128\/AAC.33.9.1470.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1582_CR22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/BF01713160","volume":"25","author":"A Wildfeuer","year":"1997","unstructured":"Wildfeuer A, Mallwitz J, Gotthardt H, Hille E, Gruber H, Dahmen G, et al. Pharmacokinetics of ampicillin, sulbactam and cefotiam in patients undergoing orthopedic surgery. Infection. 1997;25(4):258\u201362. https:\/\/doi.org\/10.1007\/BF01713160.","journal-title":"Infection"},{"issue":"6","key":"1582_CR23","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s10156-012-0431-6","volume":"18","author":"Y Yokoyama","year":"2012","unstructured":"Yokoyama Y, Matsumoto K, Yamamoto H, Iguro Y, Imoto Y, Ikawa K, et al. Pharmacokinetics of ampicillin-sulbactam and the renal function-based optimization of dosing regimens for prophylaxis in patients undergoing cardiovascular surgery. J Infect Chemother. 2012;18(6):878\u201382. https:\/\/doi.org\/10.1007\/s10156-012-0431-6.","journal-title":"J Infect Chemother"},{"key":"1582_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph192214917","author":"A Straub","year":"2022","unstructured":"Straub A, Stapf M, Fischer M, Vollmer A, Linz C, Lam TT, et al. Bone concentration of ampicillin\/sulbactam: a pilot study in patients with osteonecrosis of the jaw. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph192214917.","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"1582_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/BF01647016","volume":"18","author":"U Frank","year":"1990","unstructured":"Frank U, Schmidt-Eisenlohr E, Joos-Wurttemberger A, Hasse J, Daschner F. Concentrations of sulbactam\/ampicillin in serum and lung tissue. Infection. 1990;18(5):307\u20139. https:\/\/doi.org\/10.1007\/BF01647016.","journal-title":"Infection"},{"issue":"Suppl","key":"1582_CR26","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S0924-8579(96)80006-9","volume":"6","author":"M Wenzel","year":"1996","unstructured":"Wenzel M, Wildfeuer A, Gutsche F. Pharmacokinetics of ampicillin\/sulbactam in patients undergoing colorectal surgery: measurements in serum, the colonic wall and in tissue at the incision site. Int J Antimicrob Agents. 1996;6(Suppl):S35-39. https:\/\/doi.org\/10.1016\/S0924-8579(96)80006-9.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"1582_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF00561590","volume":"18","author":"EJ Triggs","year":"1980","unstructured":"Triggs EJ, Johnson JM, Learoyd B. Absorption and disposition of ampicillin in the elderly. Eur J Clin Pharmacol. 1980;18(2):195\u20138. https:\/\/doi.org\/10.1007\/BF00561590.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1582_CR28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/acsptsci.0c00045","volume":"3","author":"CB Landersdorfer","year":"2020","unstructured":"Landersdorfer CB, Kinzig M, Hohl R, Kempf P, Nation RL, Sorgel F. Physiologically based population pharmacokinetic modeling approach for ciprofloxacin in bone of patients undergoing orthopedic surgery. ACS Pharmacol Transl Sci. 2020;3(3):444\u201354. https:\/\/doi.org\/10.1021\/acsptsci.0c00045.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"3","key":"1582_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1152\/japplphysiol.00324.2009","volume":"107","author":"MH Tawhai","year":"2009","unstructured":"Tawhai MH, Nash MP, Lin CL, Hoffman EA. Supine and prone differences in regional lung density and pleural pressure gradients in the human lung with constant shape. J Appl Physiol (1985). 2009;107(3):912\u201320. https:\/\/doi.org\/10.1152\/japplphysiol.00324.2009.","journal-title":"J Appl Physiol (1985)"},{"issue":"70","key":"1582_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1098\/rsif.2011.0583","volume":"9","author":"C Li","year":"2012","unstructured":"Li C, Guan G, Reif R, Huang Z, Wang RK. Determining elastic properties of skin by measuring surface waves from an impulse mechanical stimulus using phase-sensitive optical coherence tomography. J R Soc Interface. 2012;9(70):831\u201341. https:\/\/doi.org\/10.1098\/rsif.2011.0583.","journal-title":"J R Soc Interface"},{"issue":"1","key":"1582_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10010017","volume":"10","author":"P Poxleitner","year":"2020","unstructured":"Poxleitner P, Ermer MA, Trittler R, Feuerstein CL, Otten J-E, Schmelzeisen R, et al. Concentration of penicillin G in jawbone affected by antiresorptive agent-related osteonecrosis following a single preoperative dose. Antibiotics. 2020;10(1):17. https:\/\/doi.org\/10.3390\/antibiotics10010017.","journal-title":"Antibiotics"},{"key":"1582_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13030366","author":"O Ristow","year":"2023","unstructured":"Ristow O, Birgel JL, Ruckschloss T, Held T, Lang K, Smielowski M, et al. Osteoradionecrosis of the jaw-comparison between bone and soft tissue injury and their influence on surgical outcomes-a retrospective cohort study. Diagnostics (Basel). 2023. https:\/\/doi.org\/10.3390\/diagnostics13030366.","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"1582_CR33","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1007\/s00784-020-03595-9","volume":"25","author":"F Ewald","year":"2021","unstructured":"Ewald F, Wuesthoff F, Koehnke R, Friedrich RE, Gosau M, Smeets R, et al. Retrospective analysis of bacterial colonization of necrotic bone and antibiotic resistance in 98 patients with medication-related osteonecrosis of the jaw (MRONJ). Clin Oral Investig. 2021;25(5):2801\u20139. https:\/\/doi.org\/10.1007\/s00784-020-03595-9.","journal-title":"Clin Oral Investig"},{"key":"1582_CR34","unstructured":"Open Systems Pharmacology Manual. https:\/\/docs.open-systems-pharmacology.org. Accessed 24 Sept 2024."},{"issue":"6","key":"1582_CR35","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jps.20322","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259\u201376. https:\/\/doi.org\/10.1002\/jps.20322.","journal-title":"J Pharm Sci"},{"issue":"6","key":"1582_CR36","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238\u201357. https:\/\/doi.org\/10.1002\/jps.20502.","journal-title":"J Pharm Sci"},{"issue":"6","key":"1582_CR37","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2165\/00003495-198733060-00003","volume":"33","author":"DM Campoli-Richards","year":"1987","unstructured":"Campoli-Richards DM, Brogden RN. Sulbactam\/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs. 1987;33(6):577\u2013609. https:\/\/doi.org\/10.2165\/00003495-198733060-00003.","journal-title":"Drugs"},{"issue":"5","key":"1582_CR38","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/cpt.3023","volume":"114","author":"JEM van der Heijden","year":"2023","unstructured":"van der Heijden JEM, Freriksen JJM, de Hoop-Sommen MA, Greupink R, de Wildt SN. Physiologically-based pharmacokinetic modeling for drug dosing in pediatric patients: a tutorial for a pragmatic approach in clinical care. Clin Pharmacol Ther. 2023;114(5):960\u201371. https:\/\/doi.org\/10.1002\/cpt.3023.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1582_CR39","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s40262-022-01161-y","volume":"61","author":"S Zhu","year":"2022","unstructured":"Zhu S, Zhang J, Lv Z, Zhu P, Oo C, Yu M, et al. Prediction of tissue exposures of meropenem, colistin, and sulbactam in pediatrics using physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2022;61(10):1427\u201341. https:\/\/doi.org\/10.1007\/s40262-022-01161-y.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1582_CR40","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.joms.2006.05.023","volume":"64","author":"AJ Rega","year":"2006","unstructured":"Rega AJ, Aziz SR, Ziccardi VB. Microbiology and antibiotic sensitivities of head and neck space infections of odontogenic origin. J Oral Maxillofac Surg. 2006;64(9):1377\u201380. https:\/\/doi.org\/10.1016\/j.joms.2006.05.023.","journal-title":"J Oral Maxillofac Surg"},{"issue":"4","key":"1582_CR41","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s10006-005-0615-7","volume":"9","author":"H Heibel","year":"2005","unstructured":"Heibel H, Scheer M, Reuther T, Hahn M, Trittler R, Egle H, et al. Ampicillin and sulbactam concentrations in the irradiated mandible after oral squamous cell cancer. Mund Kiefer Gesichtschir. 2005;9(4):214\u20139. https:\/\/doi.org\/10.1007\/s10006-005-0615-7.","journal-title":"Mund Kiefer Gesichtschir"},{"key":"1582_CR42","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST MIC distribution website, https:\/\/mic.eucast.org\/search\/. Accessed 24 Sept 2024."},{"key":"1582_CR43","unstructured":"Four Academic Societies Joint Antimicrobial Susceptibility Surveillance Program. Data from website, https:\/\/www.3ssp.jp\/database\/surgical\/mic-5090\/. Accessed 04 Sept 2025."},{"issue":"5","key":"1582_CR44","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/jac\/dkae058","volume":"79","author":"GM Assefa","year":"2024","unstructured":"Assefa GM, Roberts JA, Mohammed SA, Sime FB. What are the optimal pharmacokinetic\/pharmacodynamic targets for \u03b2-lactamase inhibitors? A systematic review. J Antimicrob Chemother. 2024;79(5):946\u201358. https:\/\/doi.org\/10.1093\/jac\/dkae058.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1582_CR45","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10928-020-09706-z","volume":"47","author":"A Dallmann","year":"2020","unstructured":"Dallmann A, Himstedt A, Solodenko J, Ince I, Hempel G, Eissing T. Integration of physiological changes during the postpartum period into a PBPK framework and prediction of amoxicillin disposition before and shortly after delivery. J Pharmacokinet Pharmacodyn. 2020;47(4):341\u201359. https:\/\/doi.org\/10.1007\/s10928-020-09706-z.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"Suppl 5","key":"1582_CR46","doi-asserted-by":"publisher","first-page":"S503","DOI":"10.1093\/clinids\/8.supplement_5.503","volume":"8","author":"G Foulds","year":"1986","unstructured":"Foulds G. Pharmacokinetics of sulbactam\/ampicillin in humans: a review. Rev Infect Dis. 1986;8(Suppl 5):S503-511. https:\/\/doi.org\/10.1093\/clinids\/8.supplement_5.503.","journal-title":"Rev Infect Dis"},{"issue":"10","key":"1582_CR47","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2165\/00003088-200544100-00002","volume":"44","author":"F Pea","year":"2005","unstructured":"Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44(10):1009\u201334. https:\/\/doi.org\/10.2165\/00003088-200544100-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1582_CR48","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/BF01062386","volume":"7","author":"M Ehrnebo","year":"1979","unstructured":"Ehrnebo M, Nilsson SO, Boreus LO. Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man. J Pharmacokinet Biopharm. 1979;7(5):429\u201351. https:\/\/doi.org\/10.1007\/BF01062386.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"11","key":"1582_CR49","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/jps.2600721103","volume":"72","author":"A Tsuji","year":"1983","unstructured":"Tsuji A, Yoshikawa T, Nishide K, Minami H, Kimura M, Nakashima E, et al. Physiologically based pharmacokinetic model for beta-lactam antibiotics I: tissue distribution and elimination in rats. J Pharm Sci. 1983;72(11):1239\u201352. https:\/\/doi.org\/10.1002\/jps.2600721103.","journal-title":"J Pharm Sci"},{"issue":"4","key":"1582_CR50","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1124\/dmd.122.001129","volume":"51","author":"P-J De Sutter","year":"2023","unstructured":"De Sutter P-J, De Cock P, Johnson TN, Musther H, Gasthuys E, Vermeulen A. Predictive performance of physiologically based pharmacokinetic modelling of beta-lactam antibiotic concentrations in adipose, bone, and muscle tissues. Drug Metab Disposit. 2023;51(4):499\u2013508. https:\/\/doi.org\/10.1124\/dmd.122.001129.","journal-title":"Drug Metab Disposit"},{"issue":"3","key":"1582_CR51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5051\/jpis.2016.46.3.152","volume":"46","author":"T Sugiura","year":"2016","unstructured":"Sugiura T, Yamamoto K, Horita S, Murakami K, Tsutsumi S, Kirita T. The effects of bone density and crestal cortical bone thickness on micromotion and peri-implant bone strain distribution in an immediately loaded implant: a nonlinear finite element analysis. J Periodontal Implant Sci. 2016;46(3):152\u201365. https:\/\/doi.org\/10.5051\/jpis.2016.46.3.152.","journal-title":"J Periodontal Implant Sci"},{"issue":"9","key":"1582_CR52","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/17425255.2022.2117607","volume":"18","author":"BCP Koch","year":"2022","unstructured":"Koch BCP, Zhao Q, Oosterhoff M, van Oldenrijk J, Abdulla A, de Winter BCM, et al. The mysteries of target site concentrations of antibiotics in bone and joint infections: what is known? A narrative review. Expert Opin Drug Metab Toxicol. 2022;18(9):587\u2013600. https:\/\/doi.org\/10.1080\/17425255.2022.2117607.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"1582_CR53","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s40262-022-01168-5","volume":"61","author":"R Garreau","year":"2022","unstructured":"Garreau R, Montange D, Grillon A, Jehl F, Ferry T, Bourguignon L, et al. Daptomycin physiology-based pharmacokinetic modeling to predict drug exposure and pharmacodynamics in skin and bone tissues. Clin Pharmacokinet. 2022;61(10):1443\u201356. https:\/\/doi.org\/10.1007\/s40262-022-01168-5.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1582_CR54","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/apm.12996","volume":"127","author":"M Tottrup","year":"2019","unstructured":"Tottrup M, Soballe K, Bibby BM, Hardlei TF, Hansen P, Fuursted K, et al. Bone, subcutaneous tissue and plasma pharmacokinetics of cefuroxime in total knee replacement patients\u2014a randomized controlled trial comparing continuous and short-term infusion. APMIS. 2019;127(12):779\u201388. https:\/\/doi.org\/10.1111\/apm.12996.","journal-title":"APMIS"},{"issue":"1","key":"1582_CR55","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1128\/AAC.01081-09","volume":"54","author":"V Zeller","year":"2010","unstructured":"Zeller V, Dzeing-Ella A, Kitzis MD, Ziza JM, Mamoudy P, Desplaces N. Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother. 2010;54(1):88\u201392. https:\/\/doi.org\/10.1128\/AAC.01081-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1582_CR56","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jiac.2014.05.006","volume":"20","author":"T Ogawa","year":"2014","unstructured":"Ogawa T, Kasahara K, Ikawa K, Shigeta J, Komatsu Y, Kuruno N, et al. Continuous ampicillin infusion as an alternative to intermittent infusion for adult inpatients: a case series. J Infect Chemother. 2014;20(10):653\u20135. https:\/\/doi.org\/10.1016\/j.jiac.2014.05.006.","journal-title":"J Infect Chemother"},{"issue":"6","key":"1582_CR57","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/jcph.1800","volume":"61","author":"T Onita","year":"2021","unstructured":"Onita T, Ikawa K, Nakamura K, Nishikawa G, Kobayashi I, Ishihara N, et al. Prostatic pharmacokinetic\/pharmacodynamic evaluation of ampicillin-sulbactam for bacterial prostatitis and preoperative prophylaxis. J Clin Pharmacol. 2021;61(6):820\u201331. https:\/\/doi.org\/10.1002\/jcph.1800.","journal-title":"J Clin Pharmacol"},{"key":"1582_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.692741","volume":"12","author":"Z Tan","year":"2021","unstructured":"Tan Z, Zhang Y, Wang C, Sun L. Physiologically based pharmacokinetic modeling of cefadroxil in mouse, rat, and human to predict concentration-time profile at infected tissue. Front Pharmacol. 2021;12:692741. https:\/\/doi.org\/10.3389\/fphar.2021.692741.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1582_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10928-016-9486-9","volume":"44","author":"MW Sadiq","year":"2017","unstructured":"Sadiq MW, Nielsen EI, Khachman D, Conil JM, Georges B, Houin G, et al. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection. J Pharmacokinet Pharmacodyn. 2017;44(2):69\u201379. https:\/\/doi.org\/10.1007\/s10928-016-9486-9.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1582_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1435906","volume":"15","author":"M Wu","year":"2024","unstructured":"Wu M, Feng K, Wu X, Liu C, Zhu S, Martins FS, et al. Prediction of tissue exposures of polymyxin-B, amikacin and sulbactam using physiologically-based pharmacokinetic modeling. Front Microbiol. 2024;15:1435906. https:\/\/doi.org\/10.3389\/fmicb.2024.1435906.","journal-title":"Front Microbiol"},{"issue":"6","key":"1582_CR61","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1128\/AAC.01119-08","volume":"53","author":"CB Landersdorfer","year":"2009","unstructured":"Landersdorfer CB, Kinzig M, Bulitta JB, Hennig FF, Holzgrabe U, Sorgel F, et al. Bone penetration of amoxicillin and clavulanic acid evaluated by population pharmacokinetics and Monte Carlo simulation. Antimicrob Agents Chemother. 2009;53(6):2569\u201378. https:\/\/doi.org\/10.1128\/AAC.01119-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1582_CR62","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/jac\/dkad223","volume":"78","author":"R Pai Mangalore","year":"2023","unstructured":"Pai Mangalore R, Peel TN, Udy AA, Peleg AY. The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting. J Antimicrob Chemother. 2023;78(10):2395\u2013405. https:\/\/doi.org\/10.1093\/jac\/dkad223.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1582_CR63","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1016\/j.xphs.2024.03.002","volume":"113","author":"Q Li","year":"2024","unstructured":"Li Q, Guan Y, Xia C, Wu L, Zhang H, Wang Y. Physiologically-based pharmacokinetic modeling and dosing optimization of cefotaxime in preterm and term neonates. J Pharm Sci. 2024;113(8):2605\u201315. https:\/\/doi.org\/10.1016\/j.xphs.2024.03.002.","journal-title":"J Pharm Sci"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01582-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:32:44Z","timestamp":1766053964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01582-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01582-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the University of W\u00fcrzburg (protocol code 51\/20-me and 143\/20-me, 2020) for studies involving humans.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients have provided written informed consent to publish this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data will be made available upon reasonable and justified request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The PBPK model described in the following work will be made available open source on Open Systems Pharmacology GitHub (https:\/\/github.com\/Open-Systems-Pharmacology).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: Maximilian Stapf, Oliver Scherf-Clavel; Methodology: Maximilian Stapf; Investigation and data acquisition: Maximilian Stapf, Anton Straub, Valentin Steinacker, Stefan Hartmann; Formal analysis: Maximilian Stapf; Writing\u2014original draft preparation: Maximilian Stapf; Writing\u2014review and editing: Anton Straub, Valentin Steinacker, Stefan Hartmann, Oliver Scherf-Clavel; Funding acquisition: Oliver Scherf-Clavel; Resources: Anton Straub, Stefan Hartmann, Valentin Steinacker, Oliver Scherf-Clavel; Project administration: Stefan Hartmann, Oliver Scherf-Clavel; Supervision: Oliver Scherf-Clavel.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}